In this episode, Drs. Laura Onderko, Zain Asad, and Aditya Bharadwaj delve into how fellows-in-training and early-career cardiologists can strategically build their research careers and assess whether ...

The 2023 European Society of Hypertension (ESH) and 2017 American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines both emphasize proper blood pressure (BP) ...

Persistent symptoms after an acute pulmonary embolism (PE) may indicate post-pulmonary embolism syndrome (PPES), a condition affecting up to 50% of patients. The most important consideration in ...

In patients with pre-existing cardiovascular disease and who are overweight or obese, but who do not have diabetes, 2.4 mg of subcutaneous semaglutide taken once weekly was superior to placebo in ...

Findings from the TACSI and TOP-CABG trials presented at ESC Congress 2025 add to discussions around antiplatelet therapy following CABG. In TACSI, simultaneously published in NEJM, researchers ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to new research published in JACC and simultaneously presented at AHA 2024. Among the highlights: ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...

In this week’s View, Dr. Eagle looks at the new ACC/AHA guideline for prevention, detection, evaluation and management of high blood pressure (BP). He then discusses new-onset right bundle branch ...

Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025. Study investigators presented findings from the REBOOT-CNIC and ...

Patients with heart failure (HF) who had an interatrial shunt inserted did not see any significant benefits overall, compared with those who underwent a placebo procedure, after a median 22-month ...

A new nasal spray form of bumetanide may reduce the tissue swelling caused by heart failure (HF) as effectively as the standard oral and intravenous formulations of the loop diuretic, based on ...

The U.S. Food and Drug Administration (FDA) has approved finerenone to treat patients with heart failure (HF) with LVEF ≥40%. The approval was based on results from the FINEARTS-HF trial, presented at ...